Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel.

Facey KM, Espin J, Kent E, Link A, Nicod E, O'Leary A, Xoxi E, van de Vijver I, Zaremba A, Benisheva T, Vagoras A, Upadhyaya S

Open source

DOI: 10.1007/s40273-021-01050-5
Published: 2021 Sep
Container: PharmacoEconomics
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40273-021-01050-5,
  title = {Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel.},
  author = {Facey KM and Espin J and Kent E and Link A and Nicod E and O'Leary A and Xoxi E and van de Vijver I and Zaremba A and Benisheva T and Vagoras A and Upadhyaya S},
  year = {2021},
  journal = {PharmacoEconomics},
  doi = {10.1007/s40273-021-01050-5},
  url = {https://doi.org/10.1007/s40273-021-01050-5}
}

RIS

TY  - JOUR
TI  - Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel.
AU  - Facey KM
AU  - Espin J
AU  - Kent E
AU  - Link A
AU  - Nicod E
AU  - O'Leary A
AU  - Xoxi E
AU  - van de Vijver I
AU  - Zaremba A
AU  - Benisheva T
AU  - Vagoras A
AU  - Upadhyaya S
PY  - 2021
JO  - PharmacoEconomics
DO  - 10.1007/s40273-021-01050-5
UR  - https://doi.org/10.1007/s40273-021-01050-5
ER  -

APA

KM, F., J, E., E, K., A, L., E, N., A, O., E, X., I, V. D. V., A, Z., T, B., A, V., & S, U. (2021). Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel.. PharmacoEconomics. https://doi.org/10.1007/s40273-021-01050-5

Source records

pubmed · retrieved 2026-11-10T09:50:07.482Z